Merck KGaA Announces $11.3 billion Acquisition of Bio‑Techne
Merck KGaA (Xetra: MKGAF) announced on 25 June 2026 that it will acquire the United States–based life‑science reagent and instrument provider Bio‑Techne in a cash transaction valued at $11.3 billion. The offer represents $73 per share, a 24 percent premium over Bio‑Techne’s closing price on 24 June, and translates into a total purchase price of approximately €9.9 billion. The acquisition is intended to broaden Merck’s laboratory equipment and life‑science tools portfolio and to strengthen its global presence in the life‑science market.
Transaction Details
| Item | Description |
|---|---|
| Purchase price | $11.3 billion ($73 per share) |
| Premium | 24 percent over the 24 June closing price |
| Closing date (Bio‑Techne) | 24 June 2026 |
| Merger announcement | 25 June 2026 |
| Legal counsel | Freshfields Bruckhaus Deringer advised Merck on the bridge financing for the deal |
Merck will finance the transaction through a bridge financing arrangement, for which Freshfields has been retained as legal counsel. The bridge loan is expected to provide the necessary liquidity to close the acquisition before the end of the calendar year.
Market Reaction
The news of the acquisition triggered a significant positive reaction in the equity markets. Bio‑Techne shares jumped 20 percent on 25 June, closing at €70.67 (USD $70.67). The Merck KGaA stock, which closed at €145.65 on 25 June, benefitted from the announcement with a notable uptick in trading volume. Analysts noted that the premium offered and the strategic fit with Merck’s existing life‑science operations underpin the favorable market response.
Corporate Profile
- Sector: Health Care
- Industry: Pharmaceuticals
- Primary Exchange: Xetra
- Currency: EUR
- Market Capitalisation: €62.29 billion
- 52‑Week Range: €100.70 – €147.70
- Price‑to‑Earnings Ratio: 24.66
Merck KGaA is a global pharmaceutical and chemicals company with research programmes in oncology, neurodegenerative, autoimmune and inflammatory diseases. The company also markets products for cardiovascular, fertility, endocrinology, over‑the‑counter products, flat‑screen technology, and other sectors such as food, cosmetics, packaging and coatings.
Strategic Implications
The acquisition expands Merck’s footprint in the life‑science tools market, complementing its existing laboratory equipment business. By acquiring Bio‑Techne’s portfolio of reagents, instruments and bioprocessing tools, Merck gains access to a broader customer base in the United States and enhances its competitive position in the global life‑science market.
The deal is expected to create synergies in research and development, manufacturing, and commercial operations. The integration process will be overseen by Merck’s global life‑sciences team and will aim for a seamless transition of product lines and customer relationships.
Conclusion
Merck KGaA’s $11.3 billion acquisition of Bio‑Techne represents a significant expansion of the company’s life‑science capabilities. The transaction is supported by a substantial premium, a clear strategic fit, and immediate positive market reception. The deal is anticipated to deliver long‑term value through enhanced product offerings, expanded market reach, and operational synergies.
